FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053702946> ?p ?o ?g. }

• W2053702946 endingPage "505" @default.
• W2053702946 startingPage "490" @default.
• W2053702946 abstract "In Brief Objective: This study aimed to clarify the incidence of hepatitis B virus (HBV) reactivation and its significance on long-term survival after partial hepatectomy in patients with HBV-related hepatocellular carcinoma (HCC), who had preoperative low HBV-DNA level of less than 2000 IU/mL. Background: HBV reactivation is a frequent complication of systemic chemotherapy in hepatitis B surface antigen–positive patients. Surgery and anesthesia result in a generalized state of immunosuppression in the immediate postoperative period. Data on HBV reactivation and its significance after partial hepatectomy are unclear. Patients and Methods: Consecutive patients from January 2006 to December 2007 were retrospectively studied. Results: HBV reactivation happened in 19.1% of patients in 1 year. There were 28 patients whose HBV reactivation was detected after the diagnosis of HCC recurrence. On multivariate analysis, hepatitis B e antigen (HBeAg) positivity, preoperative HBV-DNA above the lower limit of quantification (≥200 IU/mL), Ishak inflammation score of greater than 3, preoperative transarterial chemoembolization (TACE), operation time of more than 180 minutes, blood transfusion, and without prophylactic antiviral therapy were significantly associated with an increased risk of HBV reactivation. HBV reactivation negatively influenced postoperative hepatic functions. The posthepatectomy liver failure rate in patients with HBV reactivation was significantly higher than in those without reactivation (11.8% vs 6.4%; P = 0.002). The 3-year disease-free survival (DFS) rate and overall survival (OS) rates after resection in patients with HBV reactivation were significantly lower than those without reactivation (34.1% vs 46.0%; P = 0.009, and 51.6% vs 67.2%; P < 0.001, respectively). HBeAg positivity, detectable preoperative HBV-DNA level, high Ishak inflammation score, preoperative TACE, long operation time, and blood transfusion were independent risk factors for HBV reactivation, whereas prophylactic antiviral therapy was a protective factor. HBV reactivation, HBeAg positivity, HBV-DNA level of 200 IU/mL or more, tumor diameter greater than 5 cm, presence of satellite nodules, presence of portal vein tumor thrombus, blood transfusion, and resection margin less than 1.0 cm were independent risk factors for DFS. A HBV-DNA level of 200 IU/mL or more, an Ishak fibrosis score of 4 or greater, a tumor diameter greater than 5 cm, the presence of satellite nodules, the presence of portal vein tumor thrombus, a resection margin less than 1.0 cm, no prophylactic antiviral therapy, and HBV reactivation were independent risk factors for OS. Conclusions: HBV reactivation was common after partial hepatectomy for HBV-related HCC with a preoperative low HBV-DNA level of less than 2000 IU/mL. Routine prophylactic antiviral treatment should be given before partial hepatectomy. Hepatitis B virus (HBV) reactivation occurred in 19.1% of patients with a preoperative low HBV-DNA level of less than 2000 IU/mL in 1 year after partial hepatectomy for HBV-related hepatocellular carcinoma. Routine prophylactic antiviral treatment should be given to these patients before partial hepatectomy." @default.
• W2053702946 created "2016-06-24" @default.
• W2053702946 creator A5035061777 @default.
• W2053702946 creator A5042624998 @default.
• W2053702946 creator A5053820568 @default.
• W2053702946 creator A5054780916 @default.
• W2053702946 creator A5061972961 @default.
• W2053702946 creator A5083302885 @default.
• W2053702946 creator A5087110966 @default.
• W2053702946 creator A5089448230 @default.
• W2053702946 date "2013-03-01" @default.
• W2053702946 modified "2023-09-28" @default.
• W2053702946 title "Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels" @default.
• W2053702946 cites W150379261 @default.
• W2053702946 cites W1824036148 @default.
• W2053702946 cites W1859421852 @default.
• W2053702946 cites W1967505725 @default.
• W2053702946 cites W1967577450 @default.
• W2053702946 cites W1968261756 @default.
• W2053702946 cites W1969489445 @default.
• W2053702946 cites W1971673379 @default.
• W2053702946 cites W1977268696 @default.
• W2053702946 cites W1977303859 @default.
• W2053702946 cites W1977756844 @default.
• W2053702946 cites W1978772176 @default.
• W2053702946 cites W1981611306 @default.
• W2053702946 cites W1981900811 @default.
• W2053702946 cites W1990335264 @default.
• W2053702946 cites W1993368800 @default.
• W2053702946 cites W1996615534 @default.
• W2053702946 cites W1999928502 @default.
• W2053702946 cites W2004054613 @default.
• W2053702946 cites W2004100607 @default.
• W2053702946 cites W2005397767 @default.
• W2053702946 cites W2010723520 @default.
• W2053702946 cites W2015426704 @default.
• W2053702946 cites W2020215421 @default.
• W2053702946 cites W2030293707 @default.
• W2053702946 cites W2031686271 @default.
• W2053702946 cites W2031696610 @default.
• W2053702946 cites W2048953132 @default.
• W2053702946 cites W2061141098 @default.
• W2053702946 cites W2065954517 @default.
• W2053702946 cites W2066896673 @default.
• W2053702946 cites W2067642835 @default.
• W2053702946 cites W2073732269 @default.
• W2053702946 cites W2074004139 @default.
• W2053702946 cites W2085997970 @default.
• W2053702946 cites W2086800923 @default.
• W2053702946 cites W2087671206 @default.
• W2053702946 cites W2093733069 @default.
• W2053702946 cites W2103800302 @default.
• W2053702946 cites W2104389844 @default.
• W2053702946 cites W2106174199 @default.
• W2053702946 cites W2107315713 @default.
• W2053702946 cites W2107365595 @default.
• W2053702946 cites W2115571323 @default.
• W2053702946 cites W2125735075 @default.
• W2053702946 cites W2137512984 @default.
• W2053702946 cites W2138955583 @default.
• W2053702946 cites W2147979267 @default.
• W2053702946 cites W2149271280 @default.
• W2053702946 cites W2155791431 @default.
• W2053702946 cites W2159485751 @default.
• W2053702946 cites W3030265267 @default.
• W2053702946 cites W4243625103 @default.
• W2053702946 doi "https://doi.org/10.1097/sla.0b013e318262b218" @default.
• W2053702946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22868358" @default.
• W2053702946 hasPublicationYear "2013" @default.
• W2053702946 type Work @default.
• W2053702946 sameAs 2053702946 @default.
• W2053702946 citedByCount "97" @default.
• W2053702946 countsByYear W20537029462013 @default.
• W2053702946 countsByYear W20537029462014 @default.
• W2053702946 countsByYear W20537029462015 @default.
• W2053702946 countsByYear W20537029462016 @default.
• W2053702946 countsByYear W20537029462017 @default.
• W2053702946 countsByYear W20537029462018 @default.
• W2053702946 countsByYear W20537029462019 @default.
• W2053702946 countsByYear W20537029462020 @default.
• W2053702946 countsByYear W20537029462021 @default.
• W2053702946 countsByYear W20537029462022 @default.
• W2053702946 countsByYear W20537029462023 @default.
• W2053702946 crossrefType "journal-article" @default.
• W2053702946 hasAuthorship W2053702946A5035061777 @default.
• W2053702946 hasAuthorship W2053702946A5042624998 @default.
• W2053702946 hasAuthorship W2053702946A5053820568 @default.
• W2053702946 hasAuthorship W2053702946A5054780916 @default.
• W2053702946 hasAuthorship W2053702946A5061972961 @default.
• W2053702946 hasAuthorship W2053702946A5083302885 @default.
• W2053702946 hasAuthorship W2053702946A5087110966 @default.
• W2053702946 hasAuthorship W2053702946A5089448230 @default.
• W2053702946 hasConcept C126322002 @default.
• W2053702946 hasConcept C141071460 @default.
• W2053702946 hasConcept C159110652 @default.
• W2053702946 hasConcept C203014093 @default.
• W2053702946 hasConcept C2522874641 @default.
• W2053702946 hasConcept C2775940106 @default.

• next